CorMatrix ECM by CorMatrix Cardiovascular is for Cardiac Tissue Repair, which utilizes the company’s proprietary extracellular matrix (ECM) biomaterial technologies that harness the body’s innate ability to repair damaged cardiovascular tissue.
The company’s platform ECM Technology, an extracellular matrix biomaterial, is said to provide a natural bioscaffold that enables a patient’s own host cells to repopulate and repair damaged tissues. The CorMatrix ECM is currently FDA cleared for the reconstruction and repair of the pericardium. The additional indication expands the use of the implant to include suture-line reinforcing, buttressing for soft tissue reaproximation, repair of cannulation sites and bleeding sites, and as an intracardiac patch or pledget for tissue repair of structural problems such as septal defects.
April 03, 2024 
